InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,473.17
(
-0.25%
)
US TECH 100
19,263.20
(
-0.75%
)
Dow Jones
39,134.76
(
0.77%
)
Brent Oil
85.02
(
0.38%
)
Bitcoin
65,045.93
(
0.12%
)
Post# of 252273
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

genisi

Send PM Follow Ignore
Followers 29
Posts 5148
Boards Moderated 0
Alias Born 05/24/2006

genisi

Re: jq1234 post# 115525

Saturday, 02/26/2011 12:19:46 PM

Saturday, February 26, 2011 12:19:46 PM

Post# of 252273
I wouldn't dismiss Shire's drug already. Genzyme resumed full supply of Cerezyme market and yet about 1,000 patients were on Shire's Vpriv by end of 2010 and Shire stated in its last CC that they see a very low rate of switchbacks to Cerezyme. Bear in mind that Shire is at nearly max current manufacturing capacity for Vpriv, reimbursement takes time and Vpriv's home infusions problem was just resolved lately.
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up